TY - JOUR
T1 - Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy
AU - Vergaro, Giuseppe
AU - Franco, Annamaria Del
AU - Giannoni, Alberto
AU - Prontera, Concetta
AU - Ripoli, Andrea
AU - Barison, Andrea
AU - Masci, Pier Giorgio
AU - Aquaro, Giovanni Donato
AU - Solal, Alain Cohen
AU - Padeletti, Luigi
AU - Paßino, Claudio
AU - Emdin, Michele
PY - 2015
Y1 - 2015
N2 - Background: Left ventricular (LV) fibrosis, aßeßed by late gadolinium enhancement (LGE) at cardiac magnetic resonance imaging (MRI), is a marker of LV remodeling, and holds prognostic value in nonischemic dilated cardiomyopathy (NICM). Galectin-3 has been shown to participate in tißue fibrogenesis and to be a prognosticator in heart failure. Our aimwas to investigate the relationships between galectin-3 circulating level andmyocardial fibrosis at MRI in patients with NICM. Methods and results: One-hundred-fifty patients were enrolled (males 73%; age 58, SD 14 years), with a NICM diagnosis according to theWorld Health Organization criteria. All patients underwent a comprehensive clinical aßeßment and biohumoral characterization, including galectin-3 aßay, and cardiac MRI, with LGE aßeßment of fibrosis. Median galectin-3 value was 14.4 ng/mL (IQR 11.7-19.0 ng/mL), and LGE was detected in 106 (71%) patients. Patients with LGE had higher galectin-3 than those without (15.4, 11.8-21.0, vs 13.1, 11.7- 16.4 ng/mL, p = 0.006). Among univariate predictors of LGE presence (galectin-3, male sex, disease duration, arterial hypertension, left and right ventricular ejection fraction, left ventricular stroke volume), galectin-3 maintained its predictive value at multivariate analysis, together with sex, hypertension, disease duration and right ventricular ejection fraction. At receiver operating characteristic analysis the optimal galectin-3 cut-off for LGE prediction was 14.6 ng/mL (AUC 0.651, sensitivity 57%, specificity 73%). Conclusions: Galectin-3 is aßociated with LGE-aßeßed myocardial replacement fibrosis in patients with NICM. These results support the hypothesis that galectin-3 is involved in cardiac fibrosis and remodeling in NICM, and that its aßay may help to select subgroups at higher risk.
AB - Background: Left ventricular (LV) fibrosis, aßeßed by late gadolinium enhancement (LGE) at cardiac magnetic resonance imaging (MRI), is a marker of LV remodeling, and holds prognostic value in nonischemic dilated cardiomyopathy (NICM). Galectin-3 has been shown to participate in tißue fibrogenesis and to be a prognosticator in heart failure. Our aimwas to investigate the relationships between galectin-3 circulating level andmyocardial fibrosis at MRI in patients with NICM. Methods and results: One-hundred-fifty patients were enrolled (males 73%; age 58, SD 14 years), with a NICM diagnosis according to theWorld Health Organization criteria. All patients underwent a comprehensive clinical aßeßment and biohumoral characterization, including galectin-3 aßay, and cardiac MRI, with LGE aßeßment of fibrosis. Median galectin-3 value was 14.4 ng/mL (IQR 11.7-19.0 ng/mL), and LGE was detected in 106 (71%) patients. Patients with LGE had higher galectin-3 than those without (15.4, 11.8-21.0, vs 13.1, 11.7- 16.4 ng/mL, p = 0.006). Among univariate predictors of LGE presence (galectin-3, male sex, disease duration, arterial hypertension, left and right ventricular ejection fraction, left ventricular stroke volume), galectin-3 maintained its predictive value at multivariate analysis, together with sex, hypertension, disease duration and right ventricular ejection fraction. At receiver operating characteristic analysis the optimal galectin-3 cut-off for LGE prediction was 14.6 ng/mL (AUC 0.651, sensitivity 57%, specificity 73%). Conclusions: Galectin-3 is aßociated with LGE-aßeßed myocardial replacement fibrosis in patients with NICM. These results support the hypothesis that galectin-3 is involved in cardiac fibrosis and remodeling in NICM, and that its aßay may help to select subgroups at higher risk.
KW - Biomarkers
KW - Cardiomyopathy
KW - Dilated
KW - Late gadolinium enhancement
KW - Magnetic resonance imaging
KW - Myocardial fibrosis
UR - http://www.scopus.com/inward/record.url?scp=84933512178&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84933512178&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2015.02.008
DO - 10.1016/j.ijcard.2015.02.008
M3 - Article
C2 - 25697876
AN - SCOPUS:84933512178
VL - 184
SP - 96
EP - 100
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
IS - 1
ER -